// App-Quantinova.ai

P5-06-05 : Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer

Researchers

Presenter

  • Ivana Sestak

Principal Investigators

  • Sean Ferree

  • Itay Shemesh

  • Wesley Buckingham

  • Jack Cuzick

  • Mitchell Dowsett

Medical Centers

  • Centre for Cancer Prevention, London, Greater London, United Kingdom

  • NanoString Technologies, Inc., Seattle, WA

  • Ralph Lauren Centre for Breast Cancer Research, Royal Marsden, London, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved